Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
The first secondary objective of this study is to identify, in patients not responding to
treatment, possible changes in the polymorphisms of interest during the course of the
disease, reclassifing such polymorphisms as mutations.
The second secondary objective is to compare the control patients in terms of polymorphism
frequency on the nonpatholgoical abl fraction.
Observational Model: Cohort, Time Perspective: Cross-Sectional
The abl genotype will be determined for all subjects
baseline ; at diagnosis
Jean-Baptiste Gaillard, MD
Centre Hospitalier Universitaire de Nîmes
France: Agence Nationale de Sécurité du Médicament et des produits de santé